Impact on overall survival and progression free survival of local treatment in patients with metastatic breast cancer

Introduction: The treatment for patients with metastatic breast cancer is palliative. Traditionally, treatment of the primary tumor is reserved for palliative management of bleeding, infection or ulceration. recent studies have demonstrated increased survival of patients with metastatic breast cancer and local treatment of primary tumor. Objective: To determine the overall survival and progression- free survival in patients with metastatic breast cancer and local treatment of primary tumor. Material and methods: Patients with metastatic breast cancer at diagnosis who were treated with chemotherapy and achieved response to treatment; patients were divided into 3 groups based on the treatment: chemotherapy, chemotherapy + surgery and chemotherapy + surgery + radiotherapy. Also patients were divided by molecular phenotypes. \]Results: One hundred and twenty patients were included, 79 treated with chemotherapy alone, 21 chemotherapy + surgery and 20 with chemotherapy + surgery + radiotherapy, the probability of survival at 12 months was 71%, 84% and 94% respectively, the progression free survival at 12 months was 35%, 52% and 73% respectively. Based on molecular phenotypes, the probability of survival at 18 months was 91% luminal A, 75% luminal B, Her (+) 52% and Triple negative 42%. Conclusions: local management of the primary tumor in metastatic breast cancer provides a beneit in progression- free and overall survival in selected patients. 1665-9201 (C) 2014 Gaceta Mexicana de Oncologia. Publicado por Masson Doyma Mexico S.A. Todos los derechos reservados.